Experienced in Osteosarcoma

Yuhki Koga

Fukuoka, JP 
Experienced in Osteosarcoma
Fukuoka, JP 
OverviewLocationsClinical Research

Overview

Yuhki Koga practices in Fukuoka, Japan. Koga is rated as an Experienced expert by MediFind in the treatment of Osteosarcoma. Their top areas of expertise are Acute Megakaryoblastic Leukemia, Leukemoid Reaction, Anaplastic Large Cell Lymphoma, Bone Marrow Transplant, and Appendectomy.

Their clinical research consists of co-authoring 122 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Osteosarcoma.

Locations

Fukuoka, Japan
Other Locations
Oita, Japan
Higashi, 8128582, Japan
Nagasaki, Japan
Kurume, Japan
Isehara, 2591193, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor
Enrollment Status: Active_not_recruiting
Publish Date: July 20, 2025
Intervention Type: Drug
Study Drugs: Ramucirumab, Cyclophosphamide, Vinorelbine
Study Phase: Phase 1/Phase 2
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Synovial Sarcoma
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Synovial Sarcoma
Enrollment Status: Terminated
Publish Date: September 13, 2023
Intervention Type: Drug
Study Drugs: Ramucirumab, Gemcitabine, Docetaxel
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

122 Total Publications

Larotrectinib Monotherapy After a Subtotal Resection of Infantile Hemispheric Glioma With TPM3::NTRK1 Fusion.
Larotrectinib Monotherapy After a Subtotal Resection of Infantile Hemispheric Glioma With TPM3::NTRK1 Fusion.
Journal: Pediatric blood & cancer
Published: April 08, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Koga's expertise for a condition
ConditionClose
      View All 12 Advanced Conditions
      View All 67 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile